IGF-1 LR3 has been extensively used in muscle satellite cell research, bone biology, neuroprotection models, and metabolic signaling studies as a surrogate for sustained IGF-1 receptor activation
*For all the latest fixes, update to the latest app version 26.6.0 Feb 10 New
78 These findings have been replicated across multiple studies in animals and humans, with GLP-1R agonism consistently reducing intestinal TRLapoB 48 production and postprandial triglyceride excursions largely independent of weight loss
References Ast J, Arvaniti A, Fine NHF, Nasteska D, Ashford FB, Stamataki Z, Koszegi Z, Bacon A, Jones BJ, Lucey MA, Sasaki S, Brierley DI, Hastoy B, Tomas A, DAgostino G, Reimann F, Lynn FC, Reissaus CA, Linnemann AK, DEste E, Calebiro D, Trapp S, Johnsson K, Podewin T, Broichhagen J, Hodson DJ
A recent phase three program showed it improved A1C (a three-month average of blood sugar) more than comparators [the drugs it was tested against] and led to significant weight loss, with side effects mostly in the digestive tract (nausea, vomiting [and] diarrhea), like other GLP-1 drugs. Wegovy pill Orforglipron isnt the only pill-form GLP-1 generating excitement
This makes breathing even more difficult